deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03981614

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers

Sponsor: Academic and Community Cancer Research United

Conditions Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Carcinoma
Interventions Binimetinib Palbociclib Trifluridine and Tipiracil Hydrochloride
Updated 21 times since 2019 Last updated: Jul 30, 2024 Started: Oct 29, 2019 Primary completion: Aug 23, 2021 Completion: Jul 2, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03981614, this PHASE2 trial focuses on Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v8 and remains completed. Sponsored by Academic and Community Cancer Research United, it has been updated 21 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2019 – ~Dec 2019 · 5 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  11. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  12. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  13. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  14. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  15. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Jul 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations